Gennex Laboratories Ltd
Incorporated in 1995, Gennex Laboratories Ltd manufactures Bulk Drugs and Intermediaries[1]
- Market Cap ₹ 296 Cr.
- Current Price ₹ 13.0
- High / Low ₹ 29.0 / 11.2
- Stock P/E 20.9
- Book Value ₹ 8.12
- Dividend Yield 0.00 %
- ROCE 10.5 %
- ROE 7.96 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 51.4% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 18.4%
- Company has a low return on equity of 8.37% over last 3 years.
- Earnings include an other income of Rs.9.07 Cr.
- Promoter holding has decreased over last 3 years: -3.63%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
35 | 32 | 39 | 42 | 44 | 56 | 56 | 60 | 61 | 65 | 67 | 95 | |
33 | 30 | 34 | 37 | 42 | 52 | 52 | 53 | 56 | 61 | 54 | 84 | |
Operating Profit | 2 | 2 | 4 | 5 | 2 | 4 | 3 | 7 | 5 | 5 | 12 | 10 |
OPM % | 5% | 6% | 11% | 11% | 5% | 7% | 6% | 11% | 9% | 7% | 19% | 11% |
0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 3 | 4 | 9 | |
Interest | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Profit before tax | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 5 | 5 | 6 | 15 | 17 |
Tax % | 70% | 23% | 23% | 13% | 42% | 26% | 27% | 20% | 23% | 24% | 20% | 18% |
0 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 4 | 5 | 12 | 14 | |
EPS in Rs | 0.01 | 0.03 | 0.12 | 0.14 | 0.04 | 0.12 | 0.10 | 0.21 | 0.21 | 0.26 | 0.52 | 0.62 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | 11% |
3 Years: | 16% |
TTM: | 42% |
Compounded Profit Growth | |
---|---|
10 Years: | 36% |
5 Years: | 51% |
3 Years: | 53% |
TTM: | 20% |
Stock Price CAGR | |
---|---|
10 Years: | 22% |
5 Years: | 24% |
3 Years: | 21% |
1 Year: | -22% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 9% |
3 Years: | 8% |
Last Year: | 8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 18 | 23 | 23 |
Reserves | 13 | 13 | 16 | 18 | 19 | 21 | 23 | 27 | 31 | 61 | 148 | 162 |
3 | 4 | 2 | 4 | 2 | 5 | 5 | 7 | 10 | 1 | 1 | 1 | |
11 | 10 | 11 | 14 | 16 | 13 | 16 | 12 | 14 | 16 | 34 | 32 | |
Total Liabilities | 40 | 39 | 42 | 49 | 50 | 52 | 57 | 59 | 68 | 96 | 205 | 218 |
16 | 15 | 15 | 16 | 16 | 16 | 15 | 14 | 14 | 15 | 16 | 20 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
Investments | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 8 | 8 | 8 |
16 | 18 | 19 | 26 | 28 | 29 | 35 | 38 | 48 | 73 | 180 | 188 | |
Total Assets | 40 | 39 | 42 | 49 | 50 | 52 | 57 | 59 | 68 | 96 | 205 | 218 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 0 | 3 | -0 | 3 | 2 | -2 | -1 | 7 | -14 | -33 | -10 | |
-1 | -0 | -1 | -1 | -1 | -1 | -0 | -0 | -1 | -1 | 1 | 3 | |
0 | 0 | -2 | 1 | -2 | 1 | -0 | 2 | 2 | 21 | 79 | 2 | |
Net Cash Flow | 0 | 0 | 0 | -0 | 0 | 2 | -2 | 0 | 7 | 6 | 47 | -5 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 51 | 71 | 66 | 90 | 87 | 68 | 41 | 55 | 67 | 49 | 74 | 46 |
Inventory Days | 29 | 23 | 47 | 43 | 31 | 57 | 78 | 50 | 72 | 133 | 148 | 135 |
Days Payable | 117 | 121 | 114 | 139 | 161 | 88 | 86 | 59 | 72 | 58 | 133 | 60 |
Cash Conversion Cycle | -38 | -27 | -0 | -7 | -43 | 38 | 34 | 46 | 67 | 125 | 90 | 121 |
Working Capital Days | 65 | 88 | 76 | 106 | 93 | 86 | 119 | 152 | 148 | 240 | 470 | 400 |
ROCE % | 4% | 5% | 12% | 12% | 6% | 10% | 8% | 14% | 12% | 11% | 13% | 11% |
Documents
Announcements
-
Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories Limited Held On June 04, 2025 For Conversion Of Warrants Into Equity Shares
4 Jun - Allotment of 40 lakh equity shares on preferential basis at INR 14.75 each to promoter group.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 Jun - Newspaper publication on Audited (Standalone and Consolidated) Financial Results for the Quarter and Year ended March 31, 2025 announced by the Board in its meeting …
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual Secretarial Compliance Report for FY 2024-25 with minor board composition non-compliance noted.
-
Appointment Of Mr. Sandeep Kumar Daga As Additional (Non-Executive Non Independent) Director Of The Company
30 May - Appointment of Mr. Sandeep Kumar Daga as additional non-executive non-independent director from May 30, 2025.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
30 May - Resignation of Non-Executive Non-Independent Director Dr. S CH Dharma Rao effective May 30, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
GLL is an ISO 9001:2008, TUV, ISO 14001 and OSHAS 18000 certified vertically integrated Active Pharmaceutical Ingredient manufacturer & exporter of Bulk Drugs, Intermediates and Biotech Products in the form of Expectorants,
Muscle Relaxants, Analgesic and Anti Fungal, etc.